What is the role of corticosteroids in the management of Myasthenia Gravis?

Corticosteroids play a crucial role in the management of Myasthenia Gravis by suppressing the immune system. Myasthenia Gravis is an autoimmune disorder where the body's immune system mistakenly attacks the acetylcholine receptors at the neuromuscular junction. This leads to muscle weakness and fatigue. By using corticosteroids, which are anti-inflammatory and immunosuppressive agents, the goal is to reduce the autoimmune response against these receptors. This can lead to an improvement in muscle strength and function as the immune system's aggressiveness towards the neuromuscular junction is diminished.

The other options do not accurately reflect the role of corticosteroids in this condition. Immediate muscle relaxation is not a characteristic of corticosteroids; rather, they work over time to modulate the immune response. Enhancing the immune response contradicts the purpose of corticosteroids in treating an autoimmune condition, as the treatment aims to decrease the activity of the immune system. Lastly, increasing neuromuscular transmission does not occur directly through corticosteroid use; the improvement in transmission is a secondary effect of reduced autoantibody-mediated damage. Thus, the primary action of corticosteroids in Myasthenia Gravis is their immunosuppressive effect.